According to Intra-Cellular Therapies's latest financial reports and stock price the company's current Operating Margin is -13.89%. At the end of 2023 the company had an Operating Margin of -34.48%.
Year | Operating Margin | Change |
---|---|---|
2023 | -34.48% | -67.41% |
2022 | -105.82% | -69.74% |
2021 | -349.65% | -65.93% |
2020 | -1,026.27% | |
2017 | -41,732.65% | 19.67% |
2016 | -34,872.43% | -89.8% |
2015 | -341,797.00% | 5999.5% |
2014 | -5,603.69% | 484.56% |
2013 | -958.61% | 82.65% |
2012 | -524.84% |
Company | Operating Margin | Operating Margin differencediff. | Country |
---|---|---|---|
-856.84% | 6,068.75% | ๐บ๐ธ USA | |
-473.04% | 3,305.62% | ๐บ๐ธ USA | |
-229.85% | 1,554.79% | ๐บ๐ธ USA |
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.